Search Within

Neeta Pandit-Taskar

  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (16)
Groups
  1. Department of Medicine (43)
  2. Hematologic Malignancies, Division of (43)
  3. Molecular Imaging and Therapy Service (43)
  4. Radiology, Department of (43)
  5. GSK Faculty (27)
  6. Center for Hematologic Malignancies (26)

More Groups

People
  1. Steven Larson (23)
  2. Jorge Carrasquillo (15)
  3. Chaitanya Divgi (12)
  4. Howard Scher (11)
  5. Michael Morris (11)
  6. Susan Slovin (11)

More People

Years
  1. 2024 (2)
  2. 2023 (3)
  3. 2022 (3)
  4. 2021 (2)
  5. 2019 (2)
  6. 2016 (1)

More Years

Publications
  1. Blood (13)
  2. Journal of Clinical Oncology (12)
  3. Clinical Cancer Research (5)
  4. Journal of Nuclear Medicine (4)
  5. Cancer (2)
  6. European Journal of Nuclear Medicine and Molecular Imaging (2)

More Publications

Publishers
  1. American Society of Hematology (13)
  2. American Society of Clinical Oncology (12)
  3. American Association for Cancer Research (6)
  4. Society of Nuclear Medicine (4)
  5. Springer (3)
  6. Wiley Blackwell (2)

More Publishers

Results (43)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of the targeted alpha-particle nano-generator actinium-225 (ac-225)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML)
    Meeting Abstract

    Jurcic, J. G.; Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S. M.; Zikaras, K.; Frattini, M. G.; Maslak, P. G.; Cicic, D.; more...
    Blood (2011)

    Fulltext@MSK | Save
  • (124)I-huA33 antibody PET of colorectal cancer
    Journal Article

    Carrasquillo, J. A.; Pandit-Taskar, N.; O'Donoghue, J. A.; Humm, J. L.; Zanzonico, P.; Smith-Jones, P. M.; Divgi, C. R.; Pryma, D. A.; Ruan, S.; Kemeny, N. E.; more...
    Journal of Nuclear Medicine (2011)

    Fulltext@MSK | Save
  • Final results of a phase II study of sequential R-CHOP and yttrium-90 ibritumomab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Hamlin, P. A. Jr; Rodriguez, M. A.; Noy, A.; Portlock, C. S.; Straus, D.; McLaughlin, P.; Pro, B.; Fayad, L.; Hagemeister, F.; Wegner, B.; more...
    Blood (2010)

    Fulltext@MSK | Save
  • Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Journal Article

    Rosenblat, T. L.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Divgi, C. R.; Panageas, K. S.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Sgouros, G.; more...
    Clinical Cancer Research (2010)

    Fulltext@MSK | Save
  • FDG PET/CT (FDG PET) in evaluation of response in patients with multiple myeloma (MM) treated with bortezomib, pegylated liposomal doxorubicin, and dexamethasone
    Meeting Abstract

    Pandit-Taskar, N.; Comenzo, R. L.; Hassoun, H.; Hoover, E.; Borkar, S.; Reidel, E.; Cohen, A.; Surti, C.; Nimer, S. D.; Landau, H. J.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I/II study of docetaxel and (153)Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Rathkopf, D.; Solit, D.; Carrasquillo, J.; Larson, S.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J.; Divgi, C. R.; Slovin, S.; Kelly, W. K.; Rathkopf, D.; Gignac, G. A.; Solit, D.; Schwartz, L.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of docetaxel (Tax) and (153)Sm repetitively administered for castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Solit, D.; Rathkopf, D. E.; Carrasquillo, J. A.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Sequential cytarabine and alpha-particle immunotherapy with bismuth-213 ((213)Bi)-labeled-HuM195 (lintuzumab) for acute myeloid leukemia (AML)
    Meeting Abstract

    Rosenblat, T.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Weiss, M. A.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Larson, S. M.; Scheinberg, D. A.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Sequential administration of bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) results in rapid control of untreated high-risk multiple myeloma (MM) and improves depth of response
    Meeting Abstract

    Landau, H.; Hassoun, H.; Cohen, A.; Hoover, E.; Kewalramani, T.; Boruchov, A.; Klimek, V.; Reich, L.; Riedel, E.; Pandit-Taskar, N.; more...
    Blood (2008)

    Fulltext@MSK | Save